Orthonika

Orthonika is a UK orthopaedic medical device company and Imperial College London spin-out developing a synthetic Total Meniscus Replacement (TMR) implant for patients with irreparable knee meniscus injuries. Its lead product is designed to replicate native meniscus biomechanics using an anatomical, fiber-reinforced, proprietary polymer-based implant delivered through a minimally invasive arthroscopic procedure. The company is focused on joint preservation, pain reduction, and restoring mobility while potentially delaying or avoiding total knee arthroplasty. Orthonika has reported preclinical proof-of-concept data, grant support from Innovate UK, and progress toward a first-in-human study. In 2026, its TMR implant received FDA Breakthrough Device Designation and entry into the TAP advisory program, supporting regulatory and commercialization planning in the United States.